BetterHelp vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest online therapy platform, 30,000+ licensed therapists, Sunnyvale CA, owned by Teladoc Health. Consumer-focused text, phone, and video therapy.
About
BetterHelp is a Sunnyvale, California-based online therapy platform founded in 2013 and acquired by Teladoc Health in 2015. The platform is the world's largest online therapy service, with more than 30,000 licensed therapists and counselors available to members across the United States and internationally. BetterHelp is a direct-to-consumer service, allowing individuals to sign up, complete a brief matching questionnaire, and be paired with a therapist within days.\n\nMembers communicate with their therapist through multiple formats including text messaging, live chat, phone calls, and video sessions, offering a level of flexibility and asynchronous access that traditional therapy cannot match. Subscriptions are priced on a weekly or monthly basis with financial assistance available for lower-income members. BetterHelp has heavily invested in consumer brand awareness through podcast advertising and influencer partnerships, making it one of the most recognized names in consumer mental health.\n\nBetterHelp operates as part of Teladoc Health's mental health division alongside Teladoc's other behavioral health offerings, and the parent company's scale provides infrastructure and insurance relationship advantages. Despite facing regulatory scrutiny and advertiser criticism around messaging practices in 2022–2023, BetterHelp remains the dominant player in direct-to-consumer online therapy by volume of active clients and therapist network size.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.